Augmentation of Antidepressants with Atypical Antipsychotics in Non-Delusional Unipolar Depressed Patients with Non-Response to Antidepressant-Monotherapy A Systematic Review About Randomized Placebo Controlled Trials

作者：Erbe Sebastian^*; Gutwinski Stefan; Bschor Tom

来源：Psychiatrische Praxis, 2012, 39(2): 57-63.

DOI：10.1055/s-0031-1277013

• augmentation
• atypical antipsychotics
• treatment resistant depression

Objective Augmentation of antidepressants with atypical antipsychotics is used in depressive patients with non-response to antidepressants. We investigated the utility of this strategy.
Methods Systematic computer-based search in the online library Pubmed for randomized placebo-controlled double-blind trials (RCT) from the years 1990 to 2011.
Results We found 14 RCT about augmentation of antidepressants with atypical antipsychotics in depressive patients with non-response to antidepressants. Trials examined olanzapine, risperidone, quetiapine and aripiprazole.
Conclusions Augmentation of antidepressants with atypical antipsychotics is an alternative to the augmentation with lithium in unipolar depressive patients with non-response to antidepressants. But treatment with atypical antipsychotics as opposed to placebo increases the risk of non-compliance due to side-effects of medication. Augmentation of antidepressants with atypical antipsychotics in unipolar depression is an off-label therapy in Germany except for the augmentation with extended-release quetiapine. Knowledge about treatment strategies regarding augmentation of antidepressants with atypical antipsychotics can increase the chance of a successful treatment, but interactions and side-effects should be considered.

• 出版日期2012-3